Xencor, Inc. (XNCR)
24.00
+0.61
(+2.61%)
USD |
NASDAQ |
Oct 15, 16:00
24.02
+0.02
(+0.08%)
After-Hours: 20:00
Xencor Research and Development Expense (Quarterly) : 71.90M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 71.90M |
| March 31, 2026 | 64.67M |
| December 31, 2025 | 64.82M |
| September 30, 2025 | 54.37M |
| June 30, 2025 | 61.66M |
| March 31, 2025 | 58.58M |
| December 31, 2024 | 51.06M |
| September 30, 2024 | 58.23M |
| June 30, 2024 | 61.53M |
| March 31, 2024 | 56.87M |
| December 31, 2023 | 63.05M |
| September 30, 2023 | 64.94M |
| June 30, 2023 | 60.06M |
| March 31, 2023 | 64.38M |
| December 31, 2022 | 51.45M |
| September 30, 2022 | 53.27M |
| June 30, 2022 | 47.08M |
| March 31, 2022 | 47.76M |
| December 31, 2021 | 50.99M |
| September 30, 2021 | 50.61M |
| June 30, 2021 | 49.50M |
| March 31, 2021 | 41.41M |
| December 31, 2020 | 47.95M |
| September 30, 2020 | 44.45M |
| June 30, 2020 | 43.46M |
| Date | Value |
|---|---|
| March 31, 2020 | 33.94M |
| December 31, 2019 | 27.34M |
| September 30, 2019 | 29.77M |
| June 30, 2019 | 33.30M |
| March 31, 2019 | 28.18M |
| December 31, 2018 | 27.13M |
| September 30, 2018 | 20.95M |
| June 30, 2018 | 23.33M |
| March 31, 2018 | 26.09M |
| December 31, 2017 | 20.40M |
| September 30, 2017 | 19.41M |
| June 30, 2017 | 16.92M |
| March 31, 2017 | 15.05M |
| December 31, 2016 | 13.36M |
| September 30, 2016 | 14.07M |
| June 30, 2016 | 14.41M |
| March 31, 2016 | 10.04M |
| December 31, 2015 | 10.88M |
| September 30, 2015 | 10.58M |
| June 30, 2015 | 7.476M |
| March 31, 2015 | 5.205M |
| December 31, 2014 | 5.052M |
| September 30, 2014 | 4.953M |
| June 30, 2014 | 4.283M |
| March 31, 2014 | 4.228M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| UroGen Pharma Ltd. | 17.34M |
| MeiraGTx Holdings Plc | 57.83M |
| IDEAYA Biosciences, Inc. | 108.69M |
| Iovance Biotherapeutics, Inc. | 58.85M |